scholarly journals A double blind study to compare the efficacy of Aloe vera gel and undecylenoyl phenylalanine 2% for treatment of melisma.

2020 ◽  
Vol 27 (08) ◽  
pp. 1770-1776
Author(s):  
Farwa Naqvi ◽  
Zaib ◽  
Iram Imran ◽  
Ahmed Amin Khan Faraz ◽  
Tahira Tabussam ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Aloe Vera ◽  
P Value ◽  
Double Blind Study ◽  
Double Blind ◽  
Dermatology Department ◽  
Medical College ◽  
Aloe Vera Gel ◽  
One Way Anova

Objectives: To compare the efficacy of Aloe vera and undecylenoyl phenylalanine 2% for Melasma treatment. Study Design: Double Blind Randomized Controlled Trial. Setting: OPD Dermatology Department of DHQ Teaching Hospital, Sargodha Medical College, Sargodha. Period: October 2018 to March 2019. Material & Method: There were total 120 patients (both male and female) having 60 patients in each group. Patients with melasma were at random allocated either Aloe vera leaf gel and undecylenoyl phenylalanine 2% at night for 12 weeks. Aloe vera leaf gel and undecylenoyl phenylalanine 2% were packed in indistinguishable similar tubes numbered 1 and 2 respectively. Neither the investigators who calculated MASI score nor the patients was aware which tube carry Aloe vera leaf gel or undecylenoyl phenylalanine 2%. The patients were advised to revisit after every 4 weeks for follow-up for three months. Results: On comparison, the mean of Modified MASI score with treatment with Aloe vera leaf gel was reduced from 17.81 to 17.36. One way ANOVA was applied to compare improvement of modified MASI score at 0, 4, 8 and 12 weeks by applying Aloe vera leaf gel which was insignificant with p-value of 0.535. Mean of Modified MASI score with treatment with undecylenoyl phenylalanine 2% was reduced from 18.13 to 4.95. One way ANOVA was quite significant with undecylenoyl phenylalanine 2% with p-value of ˂ 0.001. Conclusion: Undecylenoyl phenylalanine may represent an efficious and beneficial therapy of melasma. Herbal agents which contain Aloe vera and falsely claim that they are effective should be discouraged to treat melasma.

scholarly journals A COMPARATIVE STUDY BETWEEN ETOMIDATE AND PROPOFOL AS AN INDUCTION AGENT DURING INDUCTION, LARYNGOSCOPY AND INTUBATION

2020 ◽  
Vol 4 (12) ◽  
Author(s):  
Supriya Agarwal ◽  
Vidushi Sharma
Keyword(s):  
P Value ◽  
Induction Agent ◽  
Loss Of Consciousness ◽  
Double Blind Study ◽  
Double Blind ◽  
College Hospital ◽  
Medical College ◽  
Pain On Injection ◽  
Elective Surgical Procedures ◽  
Induction Agents

Background: The objective of study was to compare Etomidate and Propofol as induction agents and their effect on Pain on injection, time to loss of consciousness and myoclonic movements. Methods: The study was carried out on 100 patients of ASA grade I and II between 18-58yrs of age of either sex enrolled for this prospective randomized double blind study, admitted in K D Medical College, Hospital & Research Center, Mathura  (U.P) and scheduled for elective surgical procedures under general anaesthesia and endotracheal intubation. Results: The incidence of pain on injection in propofol group was more as compared to etomidate group (p value <0.05). In propofol group 25(50%) patients while in etomidate group only 2(4%) patients had pain on injection. Etomidate group had significantly more myoclonic movements than propofol group (p value <0.05). In etomidate group 18(36%) patients had myoclonic movements of various severity, while in propofol group no patient had myoclonic movements. Conclusion: Incidence of apnoea on induction was more in propofol group than etomidate group but comparison was not statistically significant. Keywords: Apnea, Propofol, Etomidate.

scholarly journals Comparison of Intrathecal Fentanyl and Butorphanol as an Adjuvant to Intrathecal Bupivacaine 0.5% in Infraumbilical Surgeries- A Randomised Double Blind Study

2020 ◽  
Author(s):  
Sandip Roy Basunia ◽  
Prosenjit Mukherjee ◽  
Md Bakir Hossain Munshi
Keyword(s):  
Spinal Anaesthesia ◽  
Motor Block ◽  
Controlled Trial ◽  
Sensory Block ◽  
P Value ◽  
Double Blind Study ◽  
Hyperbaric Bupivacaine ◽  
Double Blind ◽  
Group A ◽  
Group B

Introduction: Neuraxial opioids are widely used as adjuvants to local anaesthetic as they improve quality and duration of block. Neuraxial opioids like Butorphanol and Fentanyl allow prolonged analgesia in the postoperative period and faster recovery from spinal anaesthesia. Aim: To compare the safety and efficacy of Butorphanol and Fentanyl combined with bupivacaine for spinal anaesthesia in infraumbilical surgeries. Materials and Methods: The present study was a randomised controlled trial in which 110, ASA I and II patients of either sex who underwent elective infraumbilical surgeries under spinal anaesthesia were selected. Patients were allocated randomly into two groups A (n=55) and B (n=55). Group A (F) received intrathecal 0.5% hyperbaric bupivacaine 12.5 mg (3 mL) with fentanyl 25 microgram (0.5 mL) to make it total 3.5 mL. Group B (B) received intrathecal 0.5% hyperbaric bupivacaine 12.5 mg (3 mL) with butorphanol 250 microgram (0.25 mL) and Normal Saline (NS) 0.25 mL to make it total 3.5 mL. Heart Rate (HR), Systolic and Diastolic Blood Pressure (SBP, DBP), two segment regression time of sensory block, motor block were assessed at preset intervals. Chi-square test or Fischer’s-exact test were used and a p-value ≤0.05 was considered as statistically significant. Results: Mean of two segment sensory regression time of Group A was 41.94±1.73 minutes and Group B was 50.56±4.43 minutes (p<0.0001). Time to onset of motor block in Group A was 5.28±.32 minutes and Group B was 5.27±.32 minutes (p=0.96). Mean duration of motor block in Group A was 81.23±4.87 minutes and Group B was 109.83±2.61 minutes (p<0.0001). Time to rescue analgesic was 289.27±7.37 minutes in Group A and 378.41±10.25 minutes in Group B (p<0.0001). HR, SBP and DBP were comparable among the groups. Conclusion: Intrathecal bupivacaine-butorphanol mixture was clinically better as it provided longer duration of analgesia with lesser incidences of pruritus and nausea/vomiting compared to intrathecal fentanyl-bupivacaine mixture.

scholarly journals A 40 Month Double-Blind, Randomized, Placebo-Controlled Trial on the Effect of BCc1 Nanomedicine on Survival of Metastatic and Non-Metastatic Gastric Cancer Patients

2021 ◽  
Author(s):  
Maryam Hafizi ◽  
Somayeh Kalanaky ◽  
Hassan Moaiery ◽  
Sajad Noorian ◽  
Maryam Khayamzadeh ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adverse Events ◽  
Cancer Patients ◽  
Controlled Trial ◽  
Metastatic Gastric Cancer ◽  
P Value ◽  
Double Blind ◽  
Gastric Cancer Patients

Abstract Background: Complementary experiments on nanomedicines as proper candidates for the control and treatment of cancer are widely being conducted nowadays. In the previous study, the effect of BCc1 nanomedicine, which is synthetized based on nanochelating technology, on overall survival (OS) and quality of life of gastric cancer patients was evaluated after 18 months of consumption. The OS of the same patients is reported in this study after 40 months. Methods: A double-blind, randomized, placebo-controlled, parallel, multicenter design was used in this study. 123 metastatic and non-metastatic gastric cancer patients of both genders (between 25 and 85 years old) participated in this experiment to evaluate their OS after consuming BCc1 for 40 months and to identify the adverse events of this nanomedicine. Results: The median OS of metastatic patients was 257 days in the BCc1 group [95% confidence interval (CI): 144. 142-369.858], while it was 161 days in the placebo [95% CI: 118.462-203.538]; hazard ratio (HR): 0.802 [95% CI: 0.483-1.333] (P-Value = 0.395). Similarly, the median OS of non-metastatic patients was 718 days in the BCc1 group [95% CI; 577.706-860.213], while it was 520 days in the placebo [95% CI: 460.280- 580.690]; HR: 0.807 [95% CI: 0.343,1.902] (P-Value = 0.624). There was no evidence of adverse events after 40 months.Conclusion: The OS improvement of metastatic and non-metastatic gastric cancer patients in the previous (18 months of follow-up) and current (40 months of follow-up) studies showed that BCc1 can be used along with base treatments to improve cancer patients’ OS. Trial registration: IRCTID, IRCT2017101935423N1.Registered on 19 October 2017, http://www.irct.ir/ IRCT2017101935423N1.

scholarly journals Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial

2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Asma Hayat Khan ◽  
Jawad Safdar ◽  
Saad Uddin Siddiqui
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Zinc Sulfate ◽  
Concurrent Chemoradiotherapy ◽  
Controlled Trial ◽  
Detection Threshold ◽  
P Value ◽  
Double Blind ◽  
Oral Cancer Patients

Objectives: To observe the efficacy of zinc sulfate on taste alterations in oral cancer patients receiving concurrent chemotherapy with radiotherapy. Methods: Seventy patients were randomly assigned to both intervention and control group at Oncology Section of Atomic Energy Medical Centre Karachi from September 2017 to March 2018. One group received zinc sulfate capsules (50 mg TDS daily after meals) and the other group received placebo (thrice after meals). Patients were advised to start taking capsules on the first day of their chemoradiation. Both the groups continued the capsules a month after their CCRT ended. Results: Sweet taste was most effected by cancer and its treatment followed by bitter and salty taste. Sour taste was least effected. When both the groups were compared for four tastes for detection threshold, the differences in observation at 3 stages of median IQR were not significant. For recognition threshold between zinc sulfate and placebo, no significant difference was observed in median IQR for salty taste and bitter taste. However, sweet taste (baseline p-value 0.245, end p-value 0.010, follow-up p-value 0.038) was statistically significant at end of CCRT and follow-up stage and sour taste (baseline p-value 0.24, end p-value 0.006, follow-up p-value 0.898) at end of CCRT only. Conclusion: Zinc sulfate was not found to be beneficial in preventing chemoradiation induced taste alterations. Taste and smell alterations are common in patients with cancer and do not receive sufficient support to manage taste alterations. This area requires more research to develop a comprehensive understanding of the nature and its management. Abbreviations: CCRT = Concurrent chemoradiotherapy. DT = Detection threshold. RT = Recognition threshold. AEMC = Atomic Energy Medical Centre. doi: https://doi.org/10.12669/pjms.35.3.503 How to cite this:Khan AH, Safdar J, Siddiqui SU. Efficacy of zinc sulfate on concurrent chemoradiotherapy induced taste alterations in oral cancer patients: A double blind randomized controlled trial. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.503 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A randomized, double-blind, placebo-controlled trial of a commercial Aloe vera gel for mitigation of phototherapy side-effects in vitiligo patients

2021 ◽  
Vol 28 ◽  
pp. 100442
Author(s):  
Marwa Akhdar ◽  
Robabeh Abedini ◽  
Soheil Tavakolpour ◽  
Zeinab Gholibeigian ◽  
Arghavan Azizpour
Keyword(s):  
Side Effects ◽  
Controlled Trial ◽  
Aloe Vera ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Aloe Vera Gel

scholarly journals Effects of Aloe Vera in Local Massage Oils in Alternative Medicine for the Treatment of Joint Pains: A Double Blind Study

2016 ◽  
Vol 22 (1) ◽  
pp. 8
Author(s):  
Innayat Ullah Arain ◽  
Amina Husnain ◽  
Aisha Talat
Keyword(s):  
Scientific Evidence ◽  
Aloe Vera ◽  
Visual Analogue Score ◽  
Double Blind Study ◽  
Double Blind ◽  
Oral Analgesic ◽  
Aloe Vera Gel ◽  
Group A ◽  
Group B ◽  
Epidemiological Characteristics

AbstractIntroduction:Aloe vera has been reported to have effects upon skin, joint pains and diabetes but without scientific evidence. It has never been studied in isolation as a single drug. Our study was a small study to study the symptom lowering effects of Aloe Vera gel when used in combination with a topical massage oil.Patients and Methods:A prospective double blind interventional study was conducted with patients of osteoarthritis knee randomized in two groups of patients (20 in each). Both groups were given topical oil for massage over the affected joints. They were provided oral analgesic tablets in fixed numbers and during follow up Visual analogue score and number of tablets used was taken as measure of alleviation of symptoms.Results:Both groups comprised of 20 subjects each and had similar characteristics for age/sex/laterality of joint involved. The epidemiological characteristics of the groups were similar. Group A used Topical Mas-sage Oil without addition of Aloe Vera Gel while Group B used the same oil with addition of the gel. It was observed that patients who had been given massage oil with addition of Aloe Vera gel showed less use of oral analgesics during study period and their VAS scores were less as compared to the Group A who were using the same massage oil but without Aloe Vera Gel.Conclusion:Aloe Vera as local application seems to improve pain relief and decrease oral analgesic use in patients of osteoarthritis knees who are being treated with local massage oils of alternative medical origin. Further studies need to be done to reach a conclusion.Key Words: Massage Oil, Aloe Vera, Analgesia.

The Long-Term Effects of Homeopathic Treatment of Chronic Headaches: 1 Year Follow Up

Cephalalgia ◽  
2000 ◽  
Vol 20 (9) ◽  
pp. 835-837 ◽  
Author(s):  
H Walach ◽  
T Lowes ◽  
D Mussbach ◽  
U Schamell ◽  
W Springer ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Double Blind Study ◽  
Long Term Effects ◽  
Delayed Effect ◽  
Double Blind ◽  
Homeopathic Treatment ◽  
Headache Diary ◽  
Chronic Headaches

Little is known about the long-term effects of homeopathic treatment. Following a double-blind, placebo-controlled trial of classical homeopathy in chronic headaches, we conducted a complete follow-up study of all trial participants. All patients enrolled in the double-blind study were sent a 6-week headache diary, a follow-up questionnaire. Eighty-seven of the original 98 patients enrolled returned questionnaires, 81 returned diaries. There was no additional change from the end of the trial to the 1-year follow up. The improvement seen at the end of the 12-week trial was stable after 1 year. No differential effects according to treatment after the trial could be seen. Patients with no treatment following the trial had the most improvement after 1 year. Approximately 30% of patients in homeopathic treatment will benefit after 1 year of treatment. There is no indication of a specific, or of a delayed effect of homeopathy.

scholarly journals Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis

2004 ◽  
Vol 19 (7) ◽  
pp. 739-747 ◽  
Author(s):  
L. Langmead ◽  
R. M. Feakins ◽  
S. Goldthorpe ◽  
H. Holt ◽  
E. Tsironi ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Controlled Trial ◽  
Aloe Vera ◽  
Active Ulcerative Colitis ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Aloe Vera Gel

scholarly journals Long-Term Safety and Efficacy of Prebiotic Enriched Infant Formula—A Randomized Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 1276
Author(s):  
Franka Neumer ◽  
Orenci Urraca ◽  
Joaquin Alonso ◽  
Jesús Palencia ◽  
Vicente Varea ◽  
...  
Keyword(s):  
Infant Formula ◽  
Controlled Trial ◽  
Fecal Microbiota ◽  
First Year ◽  
Double Blind Study ◽  
Double Blind ◽  
Term Infants ◽  
Intention To Treat ◽  
Prebiotic Oligosaccharides ◽  
First Year Of Life

The present study aims to evaluate the effects of an infant formula supplemented with a mixture of prebiotic short and long chain inulin-type oligosaccharides on health outcomes, safety and tolerance, as well as on fecal microbiota composition during the first year of life. In a prospective, multicenter, randomized, double-blind study, n = 160 healthy term infants under 4 months of age were randomized to receive either an infant formula enriched with 0.8 g/dL of Orafti®Synergy1 or an unsupplemented control formula until the age of 12 months. Growth, fever (>38 °C) and infections were regularly followed up by a pediatrician. Digestive symptoms, stool consistency as well as crying and sleeping patterns were recorded during one week each study month. Fecal microbiota and immunological biomarkers were determined from a subgroup of infants after 2, 6 and 12 months of life. The intention to treat (ITT) population consisted of n = 149 infants. Both formulae were well tolerated. Mean duration of infections was significantly lower in the prebiotic fed infants (p < 0.05). The prebiotic group showed higher Bifidobacterium counts at month 6 (p = 0.006), and higher proportions of Bifidobacterium in relation to total bacteria at month 2 and 6 (p = 0.042 and p = 0.013, respectively). Stools of infants receiving the prebiotic formula were softer (p < 0.05). Orafti®Synergy1 tended to beneficially impact total daily amount of crying (p = 0.0594). Supplementation with inulin-type prebiotic oligosaccharides during the first year of life beneficially modulates the infant gut microbiota towards higher Bifidobacterium levels at the first 6 months of life, and is associated with reduced duration of infections.

Sign in / Sign up

Export Citation Format

Share Document